Skip to main content

Table 1 Model input parameters

From: Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective

Input

Base case estimate

Source

Utilisation rates per 4-week cycle

 Inpatient days DEX

0.02

[27]

 Inpatient days BORT

0.0158

[27]

 Inpatient days LEN/DEX

0.0125

[27]

 Outpatient visits DEX

0.3875

[27]

 Outpatient visits BORT

0.5025

[27]

 Outpatient visits LEN/DEX

0.3325

[27]

 DEX units used

480 mg (first 4 cycles)

160 mg (cycle 5 onward)

[28]

 BORT units used

13.5 mg (first 8 cycles)

9 mg (cycle 9 onward)

[28]

 LEN/DEX unit used

525 mg

[28]

Unit costs

 Cost per inpatient day

R 4 515.80

[29]

 Cost per outpatient visit (NIC)

R 800.00

[26]

 Cost per outpatient visit (IC)

R 2 837.00

[26]

 Cost of DEX 40 mg

R 6.28

[25]

 Cost of LEN 25 mg

R 1 340.03

[16]

 Cost of BORT 1 mg/ml

R 865.47

[16]

  1. p/c per cycle, NIC non-infusion chemotherapy, IC infusion chemotherapy